Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'

F H van Bruggen; G B J Nijhuis; S U Zuidema; H J Luijendijk

doi:10.1080/17512433.2021.1874350

Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'

F H van Bruggen, G B J Nijhuis, S U Zuidema, H J Luijendijk^*

^*Corresponding author for this work

Life Course Epidemiology (LCE)

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Citation (Scopus)

66 Downloads (Pure)

Original language	English
Number of pages	2
Journal	Expert Review of Clinical Pharmacology
Volume	14
Issue number	2
DOIs	https://doi.org/10.1080/17512433.2021.1874350
Publication status	Published - 21-Jan-2021

Keywords

Serious adverse events
mortality
review
PCSK9 inhibitors
Clinicaltrials.gov

Access to Document

10.1080/17512433.2021.1874350

Response to letter to the editor re: ‘serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic reviewFinal publisher's version, 410 KBLicence: Taverne

Handle.net

Persistent link

Cite this

van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U., & Luijendijk, H. J. (2021). Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. Expert Review of Clinical Pharmacology, 14(2). https://doi.org/10.1080/17512433.2021.1874350

van Bruggen, F H ; Nijhuis, G B J ; Zuidema, S U et al. / Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review" : 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. In: Expert Review of Clinical Pharmacology. 2021 ; Vol. 14, No. 2.

@article{ca21efcb10a54bc9a2bb02f8e376069e,

title = "Response to Letter to the Editor re: {"}Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review{"}: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'",

keywords = "Serious adverse events, mortality, review, PCSK9 inhibitors, Clinicaltrials.gov",

author = "{van Bruggen}, {F H} and Nijhuis, {G B J} and Zuidema, {S U} and Luijendijk, {H J}",

year = "2021",

month = jan,

day = "21",

doi = "10.1080/17512433.2021.1874350",

language = "English",

volume = "14",

journal = "Expert Review of Clinical Pharmacology",

issn = "1751-2433",

publisher = "Taylor & Francis Group",

number = "2",

}

van Bruggen, FH, Nijhuis, GBJ, Zuidema, SU & Luijendijk, HJ 2021, 'Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'', Expert Review of Clinical Pharmacology, vol. 14, no. 2. https://doi.org/10.1080/17512433.2021.1874350

Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. / van Bruggen, F H; Nijhuis, G B J; Zuidema, S U et al.
In: Expert Review of Clinical Pharmacology, Vol. 14, No. 2, 21.01.2021.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review"

T2 - 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'

AU - van Bruggen, F H

AU - Nijhuis, G B J

AU - Zuidema, S U

AU - Luijendijk, H J

PY - 2021/1/21

Y1 - 2021/1/21

KW - Serious adverse events

KW - mortality

KW - review

KW - PCSK9 inhibitors

KW - Clinicaltrials.gov

U2 - 10.1080/17512433.2021.1874350

DO - 10.1080/17512433.2021.1874350

M3 - Comment/Letter to the editor

C2 - 33428485

SN - 1751-2433

VL - 14

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

IS - 2

ER -

van Bruggen FH, Nijhuis GBJ, Zuidema SU , Luijendijk HJ. Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. Expert Review of Clinical Pharmacology. 2021 Jan 21;14(2). doi: 10.1080/17512433.2021.1874350